SEC Filings

SEC Filings

Filing date	Description	Form	View
Feb 14, 2023	An amendment to the SC 13G filing	SC 13G/A	View HTML 0001172661-23-001167.pdf 0001172661-23-001167.rtf 0001172661-23-001167.xls
Feb 10, 2023	Report of unscheduled material events or corporate event	8-K	View HTML 0001104659-23-018505.pdf 0001104659-23-018505.rtf 0001104659-23-018505.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
Feb 08, 2023	Form of prospectus disclosing information facts events covered in both forms 424B1 424B3	424B4	View HTML 0001104659-23-012196.pdf 0001104659-23-012196.rtf 0001104659-23-012196.xls
Feb 03, 2023	Withdrawal of registration statement withdrawal request	RW WD	View HTML 0001104659-23-010050.pdf 0001104659-23-010050.rtf
Feb 03, 2023	Amended Registration statement for face-amount certificate companies	S-1/A	View HTML 0001104659-23-010227.pdf 0001104659-23-010227.rtf 0001104659-23-010227.xls
Feb 03, 2023	Registration of up to an additional 20% of securities for any offering registered on an S-1	S-1MEF	View HTML 0001104659-23-010773.pdf 0001104659-23-010773.rtf 0001104659-23-010773.xls
Feb 03, 2023	EFFECT	EFFECT	View HTML 9999999995-23-000278.pdf 9999999995-23-000278.rtf 9999999995-23-000278.xls
Feb 03, 2023	CORRESP	CORRESP	View HTML 0001104659-23-010495.pdf 0001104659-23-010495.rtf 0001104659-23-010495.xls
Feb 03, 2023	CORRESP	CORRESP	View HTML 0001104659-23-010491.pdf 0001104659-23-010491.rtf 0001104659-23-010491.xls
Feb 02, 2023	Amended Registration statement for face-amount certificate companies	S-1/A	View HTML 0001104659-23-009367.pdf 0001104659-23-009367.rtf 0001104659-23-009367.xls

Data provided by Kaleidoscope.

For investor inquiries, please contact:

ReShape Lifesciences Investor Contact:
Thomas Stankovich
Chief Financial Officer
949-276-6042
ir@ReShapeLifesci.com

Investor Contacts:
Rx Communications Group
Michael Miller
917-633-6086
mmiller@rxir.com

PRINT PAGE

EMAIL PAGE